Tags

Type your tag names separated by a space and hit enter

Soya products and serum lipids: a meta-analysis of randomised controlled trials.
Br J Nutr 2015; 114(6):831-43BJ

Abstract

Soya proteins and isoflavones have been reported to exert beneficial effects on the serum lipid profile. More recently, this claim is being challenged. The objective of this study was to comprehensively examine the effects of soya consumption on the lipid profile using published trials. A detailed literature search was conducted via MEDLINE (from 2004 through February 2014), CENTRAL (The Cochrane Controlled Clinical Trials Register) and ClinicalTrials.gov for randomised controlled trials assessing the effects of soya on the lipid profile. The primary effect measure was the difference in means of the final measurements between the intervention and control groups. In all, thirty-five studies (fifty comparisons) were included in our analyses. Treatment duration ranged from 4 weeks to 1 year. Intake of soya products resulted in a significant reduction in serum LDL-cholesterol concentration, -4.83 (95% CI -7.34, -2.31) mg/dl, TAG, -4.92 (95% CI -7.79, -2.04) mg/dl, and total cholesterol (TC) concentrations, -5.33 (95% CI -8.35, -2.30) mg/dl. There was also a significant increase in serum HDL-cholesterol concentration, 1.40 (95% CI 0.58, 2.23) mg/dl. The I² statistic ranged from 92 to 99%, indicating significant heterogeneity. LDL reductions were more marked in hypercholesterolaemic patients, -7.47 (95% CI -11.79, -3.16) mg/dl, than in healthy subjects, -2.96 (95% CI -5.28, -0.65) mg/dl. LDL reduction was stronger when whole soya products (soya milk, soyabeans and nuts) were used as the test regimen, -11.06 (95% CI -15.74, -6.37) mg/dl, as opposed to when 'processed' soya extracts, -3.17 (95% CI -5.75, -0.58) mg/dl, were used. These data are consistent with the beneficial effects of soya proteins on serum LDL, HDL, TAG and TC concentrations. The effect was stronger in hypercholesterolaemic subjects. Whole soya foods appeared to be more beneficial than soya supplementation, whereas isoflavone supplementation had no effects on the lipid profile.

Authors+Show Affiliations

1Department of Medicine,Brigham and Women's Hospital,Boston,MA 02120,USA.3Jacobi Medical Center,Albert Einstein College of Medicine,Bronx,NY 10461,USA.2Harvard School of Dental Medicine,Boston,MA 02115,USA.1Department of Medicine,Brigham and Women's Hospital,Boston,MA 02120,USA.1Department of Medicine,Brigham and Women's Hospital,Boston,MA 02120,USA.

Pub Type(s)

Journal Article
Meta-Analysis
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

26268987

Citation

Tokede, Oluwabunmi A., et al. "Soya Products and Serum Lipids: a Meta-analysis of Randomised Controlled Trials." The British Journal of Nutrition, vol. 114, no. 6, 2015, pp. 831-43.
Tokede OA, Onabanjo TA, Yansane A, et al. Soya products and serum lipids: a meta-analysis of randomised controlled trials. Br J Nutr. 2015;114(6):831-43.
Tokede, O. A., Onabanjo, T. A., Yansane, A., Gaziano, J. M., & Djoussé, L. (2015). Soya products and serum lipids: a meta-analysis of randomised controlled trials. The British Journal of Nutrition, 114(6), pp. 831-43. doi:10.1017/S0007114515002603.
Tokede OA, et al. Soya Products and Serum Lipids: a Meta-analysis of Randomised Controlled Trials. Br J Nutr. 2015 Sep 28;114(6):831-43. PubMed PMID: 26268987.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Soya products and serum lipids: a meta-analysis of randomised controlled trials. AU - Tokede,Oluwabunmi A, AU - Onabanjo,Temilola A, AU - Yansane,Alfa, AU - Gaziano,J Michael, AU - Djoussé,Luc, Y1 - 2015/08/13/ PY - 2015/8/14/entrez PY - 2015/8/14/pubmed PY - 2016/5/3/medline KW - Heart disease KW - Hypercholesterolaemia KW - Lipids KW - Nutrition KW - Prevention KW - TC total cholesterol SP - 831 EP - 43 JF - The British journal of nutrition JO - Br. J. Nutr. VL - 114 IS - 6 N2 - Soya proteins and isoflavones have been reported to exert beneficial effects on the serum lipid profile. More recently, this claim is being challenged. The objective of this study was to comprehensively examine the effects of soya consumption on the lipid profile using published trials. A detailed literature search was conducted via MEDLINE (from 2004 through February 2014), CENTRAL (The Cochrane Controlled Clinical Trials Register) and ClinicalTrials.gov for randomised controlled trials assessing the effects of soya on the lipid profile. The primary effect measure was the difference in means of the final measurements between the intervention and control groups. In all, thirty-five studies (fifty comparisons) were included in our analyses. Treatment duration ranged from 4 weeks to 1 year. Intake of soya products resulted in a significant reduction in serum LDL-cholesterol concentration, -4.83 (95% CI -7.34, -2.31) mg/dl, TAG, -4.92 (95% CI -7.79, -2.04) mg/dl, and total cholesterol (TC) concentrations, -5.33 (95% CI -8.35, -2.30) mg/dl. There was also a significant increase in serum HDL-cholesterol concentration, 1.40 (95% CI 0.58, 2.23) mg/dl. The I² statistic ranged from 92 to 99%, indicating significant heterogeneity. LDL reductions were more marked in hypercholesterolaemic patients, -7.47 (95% CI -11.79, -3.16) mg/dl, than in healthy subjects, -2.96 (95% CI -5.28, -0.65) mg/dl. LDL reduction was stronger when whole soya products (soya milk, soyabeans and nuts) were used as the test regimen, -11.06 (95% CI -15.74, -6.37) mg/dl, as opposed to when 'processed' soya extracts, -3.17 (95% CI -5.75, -0.58) mg/dl, were used. These data are consistent with the beneficial effects of soya proteins on serum LDL, HDL, TAG and TC concentrations. The effect was stronger in hypercholesterolaemic subjects. Whole soya foods appeared to be more beneficial than soya supplementation, whereas isoflavone supplementation had no effects on the lipid profile. SN - 1475-2662 UR - https://www.unboundmedicine.com/medline/citation/26268987/full_citation L2 - https://www.cambridge.org/core/product/identifier/S0007114515002603/type/journal_article DB - PRIME DP - Unbound Medicine ER -